Contemporary drug synthesis
著者
書誌事項
Contemporary drug synthesis
Wiley-Interscience, c2004
大学図書館所蔵 件 / 全12件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographical references and index
HTTP:URL=http://www.loc.gov/catdir/toc/wiley051/2004301281.html Information=Table of contents
内容説明・目次
内容説明
An integrated and insightful look at successful drug synthesis in today's drug discovery market The pharmaceutical industry is unquestionably vibrant today, with drug synthesis making a vital contribution. Whether in the early developmental stages of identifying and optimizing a lead, or the latter stages of process development and cost-effective scale-up, the ability to design elegant and economical synthetic routes is often a major factor in the eventual viability and commercial success of a drug.
Contemporary Drug Synthesis examines how leading researchers and manufacturers have integrated chemistry, biology, pharmacokinetics, and a host of other disciplines in the creation and development of leading drugs.
Authored by four of the pharmaceutical industry's most respected scientists, this timely volume:
Focuses on the processes that resulted in high-profile drugs including Lipitor, Celebrex, Viagra, Gleevec, Nexium, Claritin, and over a dozen others
Provides an in-depth introduction to each drug, followed by a detailed account of its synthesis
Organizes the drugs into fourteen therapeutic areas for clarity and ease of use
Process chemists provide an essential bridge between chemistry and the marketplace, creating scientifically practical drug processes while never losing sight of the commercial viability of those processes. Contemporary Drug Synthesis meets the needs of a growing community of researchers in pharmaceutical research and development, and is both a useful guide for practicing pharmaceutical scientists and an excellent text for medicinal and organic chemistry students.
目次
Preface v Trade Names and Their Corresponding USANs xi
Acronyms and Abbreviations xiii
Chapter 1. Antithrombotics: Ticlopidine (Ticlid) and Clopidogrel (Plavix) 1
Chapter 2. Anti-inflammatory Cyclooxygenase-2 Selective Inhibitors: Celecoxib (Celebrex) and Rofecoxib (Vioxx) 11
Chapter 3. H+/K+ -ATPase Inhibitors: Esomeprazole (Nexium) 21
Chapter 4. Protein-tyrosine Kinase Inhibitors: Imatnib (Gleevec) and Gefitinib (Iressa) 29
Chapter 5. Non-sedating Antihistamines 39
Chapter 6. Cosmeceuticals: Istretinoin (Accutane), Tazarotene (Tazorac), Minoxidil (Rogaine), and Finasteride (Propecia) 55
Chapter 7. Antibacterials: Ciprofloxacin (Cipro) and Linezolid (Zyvox) 75
Chapter 8. Atypical Antupsychotics 89
Chapter 9. Atovastatin Calcium (Lipitor) 113
Chapter 10. Antidepressants 125
Chapter 11. Anti-obesity: Orlistat (Xenical) 149
Chapter 12. Triptans for Migrane 161
Chapter 13. PDE 5 Inhibitors for Erectile Dysfunction: Sildenafil (Viagra), Vardenafil (Levitra), and Tadalafil (Cialis) 189
Chapter 14. Antiasthmatics 201
Index 214
「Nielsen BookData」 より
